After trial success, Alnylam plans to seek FDA approval for 2nd drug

Less than a year after receiving the first-ever FDA approval for a gene-silencing drug, Alnylam Pharmaceuticals Inc. now plans pushing another to market, announcing Wednesday morning that its second treatment succeeded in a late-stage trial. Cambridge-based Alnylam (Nasdaq: ALNY) develops so-called RNA interference, or RNAi, drugs that silence disease-creating genes. Its first product, the rare disease drug Onpattro, was the first such treatment to be approved by the FDA and launched last year.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news